source
- FDA delays AstraZeneca breast cancer drug camizestrant PDUFA dateThe U.S. Food and Drug Administration has extended the PDUFA target date for AstraZeneca’s breast cancer candidate camizestrant, pushing the review timeline back by a few days. No new deadline was…
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) InfectionToday, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarr…